"AbbVie's Atogepant: Long-Term Safety and Efficacy for Migraine Prevention"
AbbVie Inc (NYSE: ABBV) released positive interim analysis results for its long-term study on atogepant, a drug for migraine prevention, leading to a 2.75% drop in its stock price. The study showed consistent improvements in monthly migraine days, headache days, and acute medication use days over 48 weeks, with no new safety concerns identified. AbbVie raised its long-term revenue outlook for atogepant and another drug, expecting peak combined revenues of more than $3 billion.